chartexchange

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2026 Financial Results

GlobeNewswire Inc. | Nov 5, 2026 4:01 PM EST

Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track

Read original article